The in vitro proliferation of T cell acute lymphoblastic leukemia (T-ALL) cells in its entirety has not been well delineated because of a lack of an appropriate culture system that mimics the growth pattern in a living body. We applied a NOD/SCID mouse fetal thymus organ culture (FTOC) for leukemic cells from fresh (one case) and frozen (seven cases) bone marrow (BM) samples of children with T-ALL. Cell growth was observed in all seven samples in the culture, reaching a proliferational peak at 4 weeks, and it was calculated that the proliferation potential was 212-to 319-fold. The FTOC-derived T-ALL cells showed similarity to the original cells morphologically and immunophenotypically, still possessed clonalities and were able to regenerate overt leukemia in NOD/SCID mice. These 
Introduction
T cell acute lymphoblastic leukemia (T-ALL), like other lymphoid malignancies, is a consequence of the malignant transformation of clonal abnormal progenitor cells capable of expansion with infinite self-renewal potential. 1 This disease covers about 15% of ALL cases and has been associated with a comparatively poor prognosis based upon clinical data. 2 Because T-ALL has been subclassified using monoclonal antibodies which also react with surface antigens for normal T cell differentiation and maturation, 3, 4 leukemic cells sharing certain characteristic with their normal counterparts may respond similarly to stimulation for growth. An understanding of in vitro growth pattern of T-ALL cells in its entirety will furnish important knowledge about the proliferation and differentiation stages, dependence on particular microenvironments, and responsiveness to various cytokines of the leu-kemic cells. Short-term cultures have been used to explore conditions for the proliferation and cytoreduction of T-ALL cells. [5] [6] [7] [8] [9] Although immortalized cell lines derived from T-ALL cells have also been useful in characterizing the cell growth pattern, 10 ,11 they may not be suitable for an observation of T-ALL cells that mimic the overall growth pattern in a living body.
The receptor for IL-7 (IL-7R) has proved a critical surface molecule for the development of normal T lymphocytes. 12 Several recent reports demonstrated that IL-7R was also expressed on T-ALL cells and might play an important role in the regulation of cell growth. 5, 6, 13, 14 However, the behavior of T-ALL cells that express IL-7R is not clear.
We recently established a NOD/SCID mouse fetal thymus organ culture (NOD/SCID FTOC) that enabled us to explore the early development of T-lineage cells from human CD34 + hematopoietic progenitors. 15 By using NOD/SCID FTOC, we found that T-ALL cells from both fresh and cryopreserved samples were able to proliferate continuously in the culture system. Thus, NOD/SCID FTOC provides a novel assay system for research on T-ALL cells.
Materials and methods

Patients and leukemia cell samples
Freshly obtained or cryopreserved BM cell samples from six children with T-ALL at onset and one at relapse (male three, female three, median age 6.5 years old, range 1 to 12) were taken before treatment. Informed consents were obtained from the guardians by physicians who treated patients. The median initial white blood cell (WBC) count was 207.6 Ϯ 123.3 ϫ 10 9 /l (range 75 to 404). After separation by Ficoll-Hypaque (Amersham Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation, immunophenotyping of all leukemic cell samples was carried out using a panel of monoclonal antibodies specific for cell surface and intracytoplasmic antigens. These samples were confirmed to contain more than 90% leukemic cells based on morphological, cytochemical and immunophenotypic criteria. The viability of either fresh or thawed cell samples was always more than 92% when determined by trypan blue exclusion. Table 1 shows the clinical characteristics of the seven cases investigated.
Mice
Experimental NOD/Shi-scid (NOD/SCID) mice possessing dysfunctional mature lymphocytes and macrophages and lacking circulating complements 16 were provided by the Central Institute for Experimental Animals (Kawasaki, Japan). The mice were kept in microisolator cages on a laminar flow rack in a clean room. They were fed on an irradiated, sterile diet and given autoclaved, acidified water. Mice used for transplantation experiments were all females aged 8 to 10 weeks.
In FTOC experiments, 16-to 20-week-old male and female mice were mated and the females checked for virginal plugs (day 0 of gestation), and on day 15 of gestation. Fetal thymuses were removed for further use.
Flow cytometry and antibodies
Freshly obtained or cryopreserved BM leukemic cell samples were first enriched by density gradient centrifugation and then suspended in PBS with 0.1% deionized fraction V BSA (Sigma Chemical, St Louis, MO, USA) at a concentration of 5-10 ϫ 10 5 cells per tube for staining. In all experiments, cell samples were pre-incubated in 0.1 ml of PBS supplemented with 10 l of normal rabbit serum (Funakoshi Co, Tokyo, Japan) for 30 min to block nonspecific bindings. After washing with PBS, the cells were stained with various monoclonal antibodies (mAb) conjugated by fluorescein isothiocyanate (FITC), phycoerythrin (PE) or phycoerythrin-cyanin 5.1 (PC-5) for 30 min on ice. In some experiments, cell samples were first treated with PermeaFix (Ortho Diagnostic Systems, Tokyo, Japan) for 40 min to dissolve cell membranes and fix cells, washed with PBS and then stained with Ab specific for cytoplasmic antigens, such as Bcl-2 and TdT. The stained cells were washed with PBS, and the expressions of cell surface and cytoplasmic antigens specific for the mAb were determined by a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA) using CellQuest software. For flow cytometric analysis, FITC-conjugated mouse IgG1 and IgG2a (both as negative isotype controls); mouse anti-human CD3 (SK7), CD4 (SK3), CD8 (SK1), CD10 (N8E7), CD19 (4G7), CD45 (2D1),TCR␣␤ (WT31), HLA-DR (4G7); PE-conjugated mouse IgG1 (as a negative isotype control); and mouse anti-human CD2 (S5.2), CD3 (SK7), CD4 (SK3), CD14 (MOP9) and CD19 (4G7) antibodies were purchased from Becton Dickinson. PC-5-conjugated mouse IgG1 (as a negative isotype control), CD34 (581), CD45 (J.33) and IL-7R (R34.34) were purchased from Immunotech (Marseille, France). FITC-conjugated mouse anti-human CD14 (CLB-Mon/1) and CD7 (T55) were generous gifts from Nichirei Co. (Toyko, Japan). FITC-conjugated mouse antihuman BCL-2 (124) and TdT (HT-6) were purchased from DAKO (Carpinteria, CA, USA).
Suspension culture and cytokines
Suspension culture was performed according to a technique described previously. 17 Briefly, 2 ml aliquots of a culture mixture containing 1 ϫ 10 6 leukemic cells, DMEM (Sigma), 20% FBS (Hyclone, Logan, UT, USA), 10 Ϫ4 M mercaptoethanol (Sigma) and various cytokine combinations were plated in 12-well tissue culture plates (Becton Dickinson, Falcon No. 3043) at 37°C in a humidified atmosphere flushed with 5% CO 2 in air. Half the culture medium was refed every 4 days with the same composition. At given time points, cells were harvested from each well and analyzed phenotypically and cytometrically. In some experiments, leukemic cells derived from FTOC were cultured under the same conditions. Human IL-3, stem cell factor (SCF), IL-6, and G-CSF were donated by Kirin Brewery (Tokyo, Japan). Human IL-7 was purchased from R&D System (Minneapolis, MN, USA). All the cytokines were pure recombinant molecules and were used at concentrations that induced an optimal response in culture of human cells. The concentrations used were: 20 ng/ml for IL-3; 100 ng/ml for SCF and IL-6; 10 ng/ml for G-CSF, and 20 ng/ml for IL-7. Anti-IL-7 neutralizing antibody was purchased from Pepro Tech EC (London, UK).
FTOC
NOD/SCID FTOC was carried out with modifications as previously reported. 15, 18 Briefly, thymus lobes were dissected from NOD/SCID mouse fetus at day 15 of gestation. The lobes were then depleted of endogenous hematopoietic cells by incubation with 1.35 mM 2-deoxyguanosine (Sigma) for 5 days. The depleted thymus lobes were individually plated with 3 to 5 ϫ 10 4 leukemic cells in 30 l FTOC medium per well in Terasaki plates (Sumitomo Bakelite, Tokyo, Japan). The plates were inverted immediately to allow the lobes and cells to make contact at the bottom of a hanging drop. After 48 h of incubation, each lobe was transfered on to filter membranes (Costar, Cambridge, MA, USA; pore size 8 m) placed on sponges (Gelfoam, Upjohn, Karamazoo, MI) that had been soaked in FTOC medium. The lobes were then incubated for 2 to 10 weeks, being refed with FTOC medium every 3 days. At given time points, lobes were gently pressed under a glass coverslip in 0.1 ml of PBS containing 0.1% BSA to release cells. The isolated cells were then analyzed for morphology, cytometry and other uses. The FTOC medium used throughout the FTOC experiments was composed of RPMI-1640 medium (Sigma), 20% FBS, antibiotics, MEM nonessential amino acids solution (ϫ100, Sigma) and MEM vitamin solution (ϫ50, Sigma). FTOC was performed at 37°C in a humidified incubator flushed with 7% CO 2 . In some experiments, untreated or enriched fractions obtained by sorting from primary FTOC were reseeded for secondary FTOC at a concentration of 1 ϫ 10 5 and 1 ϫ 10 4 cells per lobe, respectively. In other experiments, IL-7 (20 ng/ml) or an anti-human IL-7 neutralizing antibody (Pepro Tech EC) were added into FTOC with routine refeeding of the culture medium.
Detection of clonal characteristics of NOD/SCID FTOC-derived T-ALL cells
In three cases, FTOC-derived T-ALL cells were examined using a PCR method to detect the clonalities of the cells, as reported previously. 19 Briefly, DNA samples were prepared from FTOC-derived T-ALL cells by standard proteinase K digestion and phenol/chloroform extraction. PCR was performed on an automated thermocycler (Gene Amp PCR system 2400; Perkin Elmer, Norwalk, CT, USA) in 50 l of 1 ϫ PCR buffer containing 500 ng genomic DNA; 200 M of each dATP, dCTP, dGTP, dTTP; 1.5 U Taq polymerase and 40 pmol of each primer. To increase specificity and yield, we employed touchdown and step-down PCR technique that has been reported elsewhere. 20 Amplification products were analyzed by electrophoresis in 2% agarose gel (Sigma, Deisenhofen, Germany) containing ethidium bromide. The positive PCR products were cut out and sequenced to show the validity of the assay. The consensus primers for the rearrangements of JH, TCR␥ and TCR␦ are listed in Table 2 .
Transplantation of FTOC-derived T-ALL cells into NOD/SCID mice
In four cases, T-ALL cells derived from primary FTOC were transplanted into NOD/SCID mice to generate leukemia. The Table 2 A list of primers used in multiplex PCR TCR Gene Primer sequences rearrangements
REV 5Ј-TTGTAGCACTGTGCGTATCC-3Ј intron Leukemia method used for transplantation have been reported elsewhere. 21 In short, 10-to 12-week-old female NOD/SCID mice were irradiated with 2.4 Gy of total body irradiation using an X-ray radiation apparatus (MBR-1520R-3; Hitachi Medico Technology, Chiba, Japan). FTOC-derived T-ALL cells were injected through a tail vein at concentrations of 1 to 5 ϫ 10 6 per mouse. To reduce the NK cell activity, the recipient mice were injected intraperitoneally with 400 l of PBS containing 20 l of anti-asialo GM1 antiserum (WAKO, Osaka, Japan) immediately before the transplantation. Identical treatments were performed on days 11, 22 and 33 after the transplantation. Mice were killed in a CO 2 chamber 4 to 6 months after the transplantation when they became ill. Various organs including BM, spleen, liver, thymus and lymph node of the mice were removed and cells in these organs released with PBS containing 5% FBS. The cell suspensions were filtered through a cell strainer (pore size 40 m, Falcon 2340; Becton Dickinson Labware, Lincoln Park, NJ, USA) to get rid of clumps and debris, and then processed for flow cytometric analysis.
Cell sorting
In four cases, T-ALL cells derived from primary FTOC were sorted on a FACS Vantage sorter (Becton Dickinson) as described previously. 22, 23 Briefly, FTOC-derived T-ALL cells were passed through a cell strainer (Falcon 2350) to remove cell aggregates. The cells were then stained with PE-conjugated IL-7R and PC-5-conjugated CD45, as described above. For negative controls, cells were stained with PE-or PC-5-conjugated mouse IgG1. A lymphocyte-sorting gate was established according to both forward and side scatters. IL-7R
+ and IL-7R
Ϫ fractions in the gate were sorted according to the intensity of the expression of IL-7R. Sorted cells were then collected respectively and re-seeded into FTOC.
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Statistic analysis
Data are presented as the mean Ϯ s.d. The statistical significance of the data was determined by Student's t-test. The level of significance was set at 0.05.
Results
Establishment of a novel culture system that favors the growth of human T-ALL Cells in NOD/SCID FTOC in its entirety
When 3 to 5 ϫ 10 5 T-ALL cells from each sample were cocultured with one thymus lobe, the average cell recovery after 4-week FTOC was 6.37 Ϯ 2.96 ϫ 10 5 /lobe for all seven samples ( Table 3 ). The number of the colonized cells per lobe after 24 h was 2.76 Ϯ 0.95 ϫ 10 3 /lobe (n ϭ 9). It was estimated that the proliferation potential would be approximately 230-fold. It corresponded with the results previously reported. 24 A time-course experiment revealed that T-ALL cells proliferated rapidly in 2 weeks (2.9 Ϯ 0.3 ϫ 10 5 /lobe at 2 weeks, approximately 100-to 150-fold), reached a proliferational peak at 4 weeks in FTOC and gradually decreased in number thereafter (Figure 1 ), but still sustained a low proliferation for up to 8 weeks (data not shown). Furthermore, T-ALL cells from fresh or cryopreserved samples gave rise to the same cell recoveries in FTOC. When 4-week FTOC-derived T-ALL cells were reseeded into secondary FTOC, they underwent a growth pattern similar to those from primary FTOC in aspects of both proliferation and phenotypes (data not shown). Through our experiments, some cell samples have been thus reseeded up to four passages without significant morphological and phenotypical changes (data not shown).
We also used suspension culture to investigate whether T-ALL cells were able to proliferate without FTOC supports. No frozen samples proliferated in suspension cultures with or without the addition of various cytokine combinations (including IL-3, SCF, IL-6 and IL-7) for over 1 week, while one fresh sample maintained a low viability for 2 weeks but did not exceed the input numbers (data not shown). When the medium was replaced with the FTOC medium, all the leukemic cells died within a week as well (data not shown). We next put FTOC-derived leukemic cells into suspension culture and they could not grow at all and died within 4 days. This (Figure 2a ). These cells were not normal T cells since in three cases that we examined, all of them still retained clonal characteristics as determined by PCR using consensus primers for TCR rearrangements (Figure 2b) .
FTOC-derived T-ALL cells were characteristically identical to the original cells
Moreover, the FTOC-derived T-ALL cells were capable of regenerating leukemia in all six NOD/SCID mice transferred with 1-5 ϫ 10 6 cells/mouse (four cases) when analyzed after 4 to 6 months ( Table 4 ). The multi-organ invasion, affecting BM, liver, spleen, thymus and lymph node, by the FTOCderived T-ALL cells confirmed their malignant characteristics. The T-ALL cells that developed in the recipient mice were phenotypically CD2 +
CD3
+ CD7 + HLA-DR Ϫ , identical to the FTOC-derived cells. However, CD34 was highly expressed on the recipient leukemic cells and these cells did not express IL-
Figure 2
Morphological and molecular characterization of the FTOC-derived T-ALL cells. (a) Photograph of FTOC-derived T-ALL cells stained with May-Grunwald-Giemsa. These cells show a typical T-ALL lymphoblastic phenotype and are identical to the original cells (case 2, magnification ϫ1000). (b) PCR detection for clonalities of FTOC-derived T-ALL cells. DNA was prepared from FTOC-derived T-ALL cells in three cases and subjected to PCR using consensus primers for JH, TCR␥ and TCR␦ rearrangements. The arrows show the positive results of specific usage of TCR␥ chain rearrangements in all three cases. The sequences shown on the right side of each graph were the results of PCR products. As S2 and S6 were from the same patient, it shows the same sequence for both samples. M, markers; 1, negative controls; 2, consensus primers. *S6 is the relapse case of S 2. 1-5 ϫ 10 6 FTOC-derived T-ALL leukemic cells were transplanted into individual NOD/SCID mice. BM and other organs were harvested 4-5 months after the transplantation when the recipient mice became ill. Cells in these organs were released and analyzed cytometrically for their expression of various surface markers. a S3-1 and S3-2 were two mice transplanted with the same cell sample, so were S5-1 and S5-2.
7R, which was different from the in vitro observations. The lack of expression of myeloid (CD14) and B-lymphoid lineage (CD19) markers excluded the possibility of contamination of normal hematopoietic progenitors in the primary FTOC.
The up-regulation of the expression of IL-7R on FTOC-derived T-ALL cells indicated there was a hierarchy in the proliferation of the leukemic cells
It was an interesting finding that FTOC-derived T-ALL cells demonstrated an up-regulation of the expression for IL-7R in all seven cases (original, 11.8 Ϯ 9.1%; after FTOC, 41.9 Ϯ Leukemia 26.1%, n ϭ 7, P Ͻ 0.05, Figure 3 ). This led us to speculate on a role for IL-7R in the proliferation of the T-ALL cells in FTOC. We next sorted the FTOC-derived T-ALL cells into IL-7R + and IL-7R Ϫ fractions and reseeded them into secondary FTOC, respectively. After 4 weeks, both fractions gave rise to a proliferation comparable to that in the primary FTOC. However, the proliferational potential of IL-7R
Ϫ and IL-7R + cells differed. The IL-7R Ϫ fraction had a higher cell recovery than IL-7R
+ cells in secondary FTOC in all four cases investigated (P Ͻ 0.05, Figure 4b) . Furthermore, cytometric analysis showed a predominant generation of IL-7R + cells from both fractions after a 4-week FTOC (88.9 Ϯ 6.2% from IL-7 + and 78.0 Ϯ 12.4% from IL-7
Ϫ fractions, n ϭ 4), denoting a con-
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Figure 3
Cytometric profiles of the expression of IL-7R on original and FTOC-derived T-ALL leukemic cells.
tinuous input of IL-7R Ϫ cells into the IL-7R + fraction ( Figure  4a) . When IL-7 or an anti-human IL-7 neutralizing antibody as added into the primary FTOC in four samples, the cell recoveries for 4-week FTOC were identical to those without addition of either factors. Cytometric analysis of the FTOCderived T-ALL cells also did not show phenotypic changes by staining with various T-ALL specific markers and IL-7R, indicating that IL-7 is not responsible for the proliferational change and up-regulation of IL-7R expression for T-ALL cells in FTOC (data not shown).
Discussion
Short-term cultures may not be appropriate for studying the entire growth pattern of T-ALL cells because of the low proliferation and expeditious death of the cells, especially from cryopreserved samples. On the other hand, cell lines derived from primary T-ALL cells were mostly grown from a small fraction of cells that had survived in culture and were dependent on specific culture conditions such as cytokines or stromal cells. 10, 11, 25, 26 In the present study, we found that T-ALL cells could proliferate vigorously in NOD/SCID FTOC without addition of exogenous factors. The FTOC-derived T-ALL cells were not ordinary cell lines because they were unable to grow again in suspension cultures with or without the addition of cytokines in all seven cases investigated. 27 Rather, they were not arrested at a discrete stage and showed a growth pattern similar to normal T-lineage progenitors in that they diverged according to their proliferation potential in FTOC (which could be defined by the expression of IL-7R), suggesting that there was a hierarchy within the counterparts of T-ALL cells. Because we did not find mature T cells, myeloid or B-lineage cells either in the FTOC or in transplanted mice, the T-ALL cells that developed in FTOC were also not able to differentiate into normal cells, nor could they differentiate into other cell lineages. Since T-ALL lymphoblasts are transformed T-lineage progenitors, like their normal counterparts, FTOC may provide a suitable growth microenvironment for T-ALL cells in vitro that mimicks bona fide growth in a living body. It may correspond to a previous finding that B-lineage ALL cells also required bone marrow stromal cells for optimal growth. Most interestingly, the proportions of IL-7R-positive cells were increased in all seven cases in FTOC. Recent research revealed an ambiguous role for the expression of IL-7R on cultured T-ALL cells, which was not definitively correlated with the IL-7 responsiveness, indicating that a complex regulation might govern the growth of leukemic blasts. 6 Nevertheless, in our experiments, IL-7R + and IL-7R Ϫ T-ALL cells produced a distinct difference in the proliferation in secondary FTOC, suggesting that there exists a pathway from IL-7R
Ϫ to IL-7R + in the T-ALL cell counterparts. Our result was consistent with what had been obtained in the normal model: that IL-7R is expressed on fractionally committed T cell progenitors, but not on primitive hematopoietic stem cells. 29 It is worth noting that in four cases examined, the human T-ALL cells that developed in NOD/SCID mice were mostly CD34 +
IL-7R
Ϫ (93.1 Ϯ 9.6%, n ϭ 6). Considering that the expressions of CD34 and IL-7R on original or FTOC-derived T-ALL cells were not always related, the leukemic cells might be selected again in vivo. Only CD34 + IL-7R Ϫ cells, which represented the most immature and highly proliferative fraction in the T-ALL counterparts, might be able to proliferate continuously in NOD/SCID mice.
In the present study, we could not determine the factors responsible for the proliferation of T-ALL cells in NOD/SCID FTOC. Nor could we explain why the proportion of IL-7R + cells increased. Since the mouse fetal thymus did not secrete human IL-7 and because the responsiveness to IL-7 was not definitely related to IL-7R expression, 6 IL-7 itself did not seem to be responsible for the growth of human T-ALL cells in murine FTOC, while the changing of the expression of IL-7R might be controlled intrinsically. Actually, the addition of IL-7 or a neutralizing antibody to human IL-7 did not give rise to proliferational or morphological changes of T-ALL cells in FTOC. Page et al 30 previously showed that the 76-kDa subunit of IL-7R was responsible for proliferation of T cells and that the 90-kDa subunit of IL-7R was expressed by unstimulated T cells. Since the antibody we used to stain IL-7R reacted with the 76-kDa subunit, it was unlikely that the use of the specific subunit could lead to this discrepancy of our results. It has Leukemia been reported that a particular type of T-ALL cells produce G-CSF as an autocrine growth stimulation 31 and this led us to speculate that T-ALL lymphoblasts secrete some other factors to support themselves. Since normal T cell development is mainly thymus-dependent, direct contact between T-ALL cells and the thymic stroma may also contribute to their proliferation in FTOC. Differential display of the transcripts from T-ALL lymphoblasts before and after FTOC may also pinpoint the molecules most responsible for the cell proliferation.
In conclusion, we established a novel culture system that favors T-ALL cells growing in NOD/SCID FTOC. Through our experiments, we propose that there may be a hierarchy within the T-ALL lymphoblasts, which can be defined by the expression of IL-7R. IL-7R
Ϫ cells represent a more primitive fraction having high proliferation potential and may be responsible for the ability to regenerate leukemia in NOD/SCID mice, while the IL-7R
+ fraction more probably represents for an exhausted population. Further experiments using transplantation of both fractions separately may clarify this point. The current study should provide useful information for research on T-ALL cells and may facilitate the establishment of novel therapeutic modalities.
